Fernando A Goldbaum

Title: Innovations of Fernando A Goldbaum

Introduction

Fernando A Goldbaum is a notable inventor based in Argentina. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric proteins. His work focuses on creating innovative solutions for immune responses and vaccine development.

Latest Patents

Fernando A Goldbaum holds a patent for "Isolated Chimeric Proteins Of Modified Lumazine Synthase." This invention includes isolated chimeric proteins that consist of up to ten copies of peptides, polypeptides, or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. The patent also covers isolated nucleotide sequences that code for these chimeric proteins, as well as vectors, plasmids, and transformed cells used for expressing the proteins. Additionally, it includes monoclonal and polyclonal antibodies induced by the chimeric proteins, hybridomas producing these antibodies, and various applications such as vaccines and pharmaceutical compounds. The invention also describes a method to induce an immune response in higher organisms through the administration of effective amounts of the vaccines and pharmaceutical compounds. Furthermore, it encompasses biosensors that utilize the chimeric proteins and protein conjugates formed by the chimeric proteins and a ligand bound by covalent and noncovalent bonds.

Career Highlights

Fernando A Goldbaum is associated with Goldgene LLC, where he continues to advance his research and innovations. His work has been instrumental in the development of new biotechnological applications that have the potential to impact healthcare significantly.

Collaborations

Fernando collaborates with Diego A Laplagne, contributing to the advancement of their shared research interests and projects.

Conclusion

Fernando A Goldbaum's innovative work in the field of biotechnology, particularly with chimeric proteins, showcases his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in vaccine development and immune response mechanisms.